

## NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- HER2 positive endometrial cancer - Stage I, II, III or IV endometrial serous or carcinosarcoma - have not had chemotherapy for treatment of this cancer

---

**Exclusion Criteria:**

- pelvic radiation therapy used to treat the tumor - history of serious heart or lung disease - plan for hysterectomy after chemotherapy

### Conditions & Interventions

**Conditions:**

Cancer, Women's Health

**Keywords:**

endometrial carcinosarcoma, Endometrial Serous Adenocarcinoma, Clinics and Surgery Center (CSC)

### More Information

**Description:** We are doing this study to see if we can lower the chance of endometrial cancer coming back and causing death by adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs. We want to find out if this approach is better or worse than the usual approach for your endometrial cancer. The usual approach is defined as care most people get for endometrial cancer, which in this case would be chemotherapy.

**Study Contact:** Britt Erickson - bkeric@umn.edu

**Principal Investigator:** Britt Erickson

**Phase:** PHASE3

**IRB Number:** SITE00001733

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.